nomacopan (rVA576)
Phase 3Small molecule
nomacopan (rVA576) is one of 39 small molecule programs targeting Bullous Pemphigoid. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
37 competitors in Bullous Pemphigoid
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Rayos
RRoxane Laboratories
Approved
Avlosulfon
AAlmirall, S.A.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Imuran
LLegacy Health System
Approved
Rituxan
RochePhase 3
Fasenra
AstraZenecaPhase 3
Xolair
RochePhase 3
Vyvgart
ArgenxPhase 3
Mabthera
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for nomacopan (rVA576). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAKARI Therapeutics